Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099695 | 0.90 | NR1H2 (0.58) | NR1H2NR1H3SIGMAR1PARP1CA1 | |
| SCHEMBL8448438 | 0.90 | NR1H2 (0.58) | NR1H2NR1H3SIGMAR1PARP1CA1 | |
| SCHEMBL5369120 | 0.89 | NR1H2 (0.54) | NR1H2NR1H3SIGMAR1PARP1CA1 | |
| SCHEMBL6099031 | 0.89 | NR1H2 (0.54) | NR1H2NR1H3SIGMAR1PARP1CA1 | |
| SCHEMBL6100941 | 0.88 | NR1H2 (0.52) | NR1H2NR1H3SIGMAR1PARP1CA1 | |
| SCHEMBL6132912 | 0.88 | NR1H2 (0.52) | NR1H2NR1H3SIGMAR1PARP1CA1 | |
| SCHEMBL3506136 | 0.87 | NR1H2 (0.54) | NR1H2NR1H3SIGMAR1PARP1CA1 | |
| SCHEMBL8229118 | 0.87 | NR1H2 (0.54) | NR1H2NR1H3PARP1CA1CA2 | |
| SCHEMBL3495123 | 0.87 | NR1H2 (0.54) | NR1H2NR1H3SIGMAR1PARP1CA1 | |
| SCHEMBL5369316 | 0.86 | NR1H2 (0.46) | NR1H2NR1H3OPRK1PARP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094779-B2 | Piperazine oxime dervatives having NK-1 receptor antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-22 | — | — | US | disclosed |
| EP-1406894-B1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2004-12-22 | — | — | EP | disclosed |
| US-20040176389-A1 | Piperazine oxime dervatives having nk-1 receptor antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176389-A1 | Piperazine oxime dervatives having nk-1 receptor antagonistic activity | TACR2, OPRK1, TACR1 | NR1H2 546/4885NR1H3 803/4885SIGMAR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.